{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:29:14Z","timestamp":1790141354302,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>When brain cancer relapses, treatment options are scarce. The use of molecularly matched targeted therapies may provide a feasible and efficacious way to treat individual patients based on the molecular tumor profile. Since little information is available on this strategy in neuro-oncology, we retrospectively analyzed the clinical course of 41 patients who underwent advanced molecular testing at disease relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed Sanger sequencing, targeted next\u00a0generation sequencing, and immunohistochemistry for analysis of potential targets, including programmed death ligand 1, cyclin D1, phosphorylated mechanistic target of rapamycin, telomerase reverse transcriptase promoter mutation, cyclin-dependent kinase inhibitor 2A\/B deletion, or <jats:italic>BRAF-V600E<\/jats:italic> mutation. In selected patients, whole exome sequencing was conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The investigation included 41 patients, of whom 32 had isocitrate dehydrogenase (<jats:italic>IDH<\/jats:italic>) wildtype glioblastoma. Molecular analysis revealed actionable targets in 31 of 41 tested patients and 18 patients were treated accordingly (matched therapy group). Twenty-three patients received molecularly unmatched empiric treatment (unmatched therapy group). In both groups, 16 patients were diagnosed with recurrent <jats:italic>IDH<\/jats:italic> wildtype glioblastoma. The number of severe adverse events was comparable between the therapy groups. Regarding the <jats:italic>IDH<\/jats:italic> wildtype glioblastoma patients, median progression-free survival (mPFS) and median overall survival (mOS) were longer in the matched therapy group (mPFS: 3.8 versus 2.0\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.0057; mOS: 13.0 versus 4.3\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.0357).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These encouraging data provide a rationale for molecularly matched targeted therapy in glioma patients. For further validation, future study designs need to additionally consider the prevalence and persistence of actionable molecular alterations in patient tissue.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04050-w","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T03:25:06Z","timestamp":1660274706000},"page":"3513-3526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma"],"prefix":"10.1007","volume":"149","author":[{"given":"Lazaros","family":"Lazaridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pierscianek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sied","family":"Kebir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"4050_CR1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14737140.2017.1344553","volume":"17","author":"A Abdelaziz","year":"2017","unstructured":"Abdelaziz A, Vaishampayan U (2017) Cabozantinib for the treatment of kidney cancer. Expert Rev Anticancer Ther 17:577\u2013584","journal-title":"Expert Rev Anticancer Ther"},{"key":"4050_CR2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","volume":"16","author":"K Aldape","year":"2019","unstructured":"Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ (2019) Challenges to curing primary brain tumours. Nat Rev Clin Oncol 16:509\u2013520","journal-title":"Nat Rev Clin Oncol"},{"key":"4050_CR3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW, Glass Consortium (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576:112\u2013120","journal-title":"Nature"},{"key":"4050_CR4","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","volume":"31","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212\u20133218","journal-title":"J Clin Oncol"},{"key":"4050_CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","volume":"15","author":"TM Bauer","year":"2020","unstructured":"Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E (2020) Brain penetration of lorlatinib: cumulative Incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol 15:55\u201365","journal-title":"Target Oncol"},{"key":"4050_CR6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","volume":"395","author":"PL Bedard","year":"2020","unstructured":"Bedard PL, Hyman DM, Davids MS, Siu LL (2020) Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395:1078\u20131088","journal-title":"Lancet"},{"key":"4050_CR7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41568-019-0226-5","volume":"20","author":"J Bi","year":"2020","unstructured":"Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS (2020) Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer 20:57\u201370","journal-title":"Nat Rev Cancer"},{"key":"4050_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-016-2237-3","volume":"130","author":"DT Blumenthal","year":"2016","unstructured":"Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, Yust-Katz S, Lokiec A, Ram Z, Ross JS, Ali SM, Yair R, Soussan-Gutman L, Bokstein F (2016) Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neurooncol 130:211\u2013219","journal-title":"J Neurooncol"},{"key":"4050_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1078-0432.CCR-17-0963","volume":"24","author":"SA Byron","year":"2018","unstructured":"Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD (2018) Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res 24:295\u2013305","journal-title":"Clin Cancer Res"},{"key":"4050_CR10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrc.2016.35","volume":"16","author":"TH Carr","year":"2016","unstructured":"Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC (2016) Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer 16:319\u2013329","journal-title":"Nat Rev Cancer"},{"key":"4050_CR11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-019-0834-y","volume":"21","author":"C Chaul-Barbosa","year":"2019","unstructured":"Chaul-Barbosa C, Marques DF (2019) How we treat recurrent glioblastoma today and current evidence. Curr Oncol Rep 21:94","journal-title":"Curr Oncol Rep"},{"key":"4050_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstrom P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varnas K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, Zhang L, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, Malmquist J, Revunov E, Vazquez-Romero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV, Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE (2021) Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res 27:189\u2013201","journal-title":"Clin Cancer Res"},{"key":"4050_CR13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jtho.2019.08.1359","volume":"14","author":"M D'Arcangelo","year":"2019","unstructured":"D\u2019Arcangelo M, Tassinari M, De Marinis D, Delmonte A, Galetta D, Cecere F, Pilotto S, Zanelli F, Bonanno L, Landi L, D\u2019Inca F, Cappuzzo F (2019) \u2019Phase II single arm study of CABozantinib in non-small cell lung cancer patients with MET deregulation (CABinMET). J Thorac Oncol 14:664","journal-title":"J Thorac Oncol"},{"key":"4050_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ (2016) Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18. Breast Cancer Res 18:67","journal-title":"Breast Cancer Res"},{"key":"4050_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","volume":"16","author":"TM Johanns","year":"2018","unstructured":"Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G (2018) Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults With BRAF-mutated high-grade glioma. J Natl Compr Canc Netw 16:4\u201310","journal-title":"J Natl Compr Canc Netw"},{"key":"4050_CR16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189\u2013193","journal-title":"Science"},{"key":"4050_CR17","first-page":"vdz060","volume":"2","author":"T Kessler","year":"2020","unstructured":"Kessler T, Berberich A, Casalini B, Druschler K, Ostermann H, Dormann A, Walter S, Hai L, Schlesner M, Herold-Mende C, Jungk C, Unterberg A, Bendszus M, Sahm K, von Deimling A, Winkler F, Platten M, Wick W, Sahm F, Wick A (2020) \u2019Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol Adv 2:vdz060","journal-title":"Neurooncol Adv"},{"key":"4050_CR18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","volume":"25","author":"H Kim","year":"2015","unstructured":"Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Muller F, Hu J, Sloan AE, Cohen ML, Van Meir EG, Scarpace L, Laird PW, Weinstein JN, Lander ES, Gabriel S, Getz G, Meyerson M, Chin L, Barnholtz-Sloan JS, Verhaak RG (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25:316\u2013327","journal-title":"Genome Res"},{"issue":"692\u2013704","key":"4050_CR19","volume":"35","author":"V K\u00f6rber","year":"2019","unstructured":"Korber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, Fletcher MNC, Jones D, Hentschel B, Lamszus K, Tonn JC, Schackert G, Sabel M, Felsberg J, Zacher A, Kaulich K, Hubschmann D, Herold-Mende C, von Deimling A, Weller M, Radlwimmer B, Schlesner M, Reifenberger G, Hofer T, Lichter P (2019) Evolutionary trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell 35(692\u2013704):e12","journal-title":"Cancer Cell"},{"key":"4050_CR20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X, Shiva investigators (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324\u20131334","journal-title":"Lancet Oncol"},{"key":"4050_CR21","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/ijc.32358","volume":"145","author":"J Leichsenring","year":"2019","unstructured":"Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Frohlich M, Uhrig S, Kazdal D, Allgauer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Moller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Frohling S, Stenzinger A (2019) Variant classification in precision oncology. Int J Cancer 145:2996\u20133010","journal-title":"Int J Cancer"},{"key":"4050_CR22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, De Salvo GL, Brandes AA, Eoli M, Ruda R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bellu L, Pambuku A, Farina M, Magni G, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110\u2013119","journal-title":"Lancet Oncol"},{"key":"4050_CR23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444\u2013451","journal-title":"Lancet"},{"key":"4050_CR24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820","journal-title":"Acta Neuropathol"},{"key":"4050_CR25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251","journal-title":"Neuro Oncol"},{"key":"4050_CR26","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O\u2019Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D\u2019Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24:4154\u20134161","journal-title":"Clin Cancer Res"},{"key":"4050_CR27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","volume":"31","author":"S Park","year":"2020","unstructured":"Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ (2020) A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 31:1397\u20131404","journal-title":"Ann Oncol"},{"key":"4050_CR28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI (2016) \u2019Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer non-small cell lung cancer, and other solid tumors. Cancer Discov 6:740\u2013753","journal-title":"Cancer Discov"},{"key":"4050_CR29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clgc.2019.05.002","volume":"17","author":"G Peverelli","year":"2019","unstructured":"Peverelli G, Raimondi A, Ratta R, Verzoni E, Bregni M, Cortesi E, Carteni G, Fornarini G, Facchini G, Buti S, Galli L, Tucci M, Prisciandaro M, Procopio G (2019) Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population. Clin Genitourin Cancer 17:291\u2013298","journal-title":"Clin Genitourin Cancer"},{"key":"4050_CR30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-020-02679-6","volume":"585","author":"J Photopoulos","year":"2020","unstructured":"Photopoulos J (2020) \u2019The future of tissue-agnostic drugs. Nature 585:16","journal-title":"Nature"},{"key":"4050_CR31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd (2020) Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol 21:508\u2013518","journal-title":"Lancet Oncol"},{"key":"4050_CR32","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, Giannone V, D\u2019Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE (2017) Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18:1307\u20131316","journal-title":"Lancet Oncol"},{"key":"4050_CR33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","volume":"28","author":"MA Qazi","year":"2017","unstructured":"Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK (2017) Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol 28:1448\u20131456","journal-title":"Ann Oncol"},{"key":"4050_CR34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-020-2715-9","volume":"587","author":"N Rajewsky","year":"2020","unstructured":"Rajewsky N, Almouzni G, Gorski SA, Aerts S, Amit I, Bertero MG, Bock C, Bredenoord AL, Cavalli G, Chiocca S, Clevers H, De Strooper B, Eggert A, Ellenberg J, Fernandez XM, Figlerowicz M, Gasser SM, Hubner N, Kjems J, Knoblich JA, Krabbe G, Lichter P, Linnarsson S, Marine JC, Marioni JC, Marti-Renom MA, Netea MG, Nickel D, Nollmann M, Novak HR, Parkinson H, Piccolo S, Pinheiro I, Pombo A, Popp C, Reik W, Roman-Roman S, Rosenstiel P, Schultze JL, Stegle O, Tanay A, Testa G, Thanos D, Theis FJ, Torres-Padilla ME, Valencia A, Vallot C, van Oudenaarden A, Vidal M, Voet T, Groups LifeTime Community Working (2020) LifeTime and improving European healthcare through cell-based interceptive medicine. Nature 587:377\u2013386","journal-title":"Nature"},{"key":"4050_CR35","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/cncr.33378","volume":"127","author":"DA Reardon","year":"2021","unstructured":"Reardon DA, Kim TM, Frenel JS, Simonelli M, Lopez J, Subramaniam DS, Siu LL, Wang H, Krishnan S, Stein K, Massard C (2021) \u2019Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127:1620\u20131629","journal-title":"Cancer"},{"key":"4050_CR36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/1078-0432.CCR-15-2089","volume":"23","author":"R Reinartz","year":"2017","unstructured":"Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Kupper M, Rauschenbach L, Fimmers R, Shepherd TM, Trageser D, Till A, Schafer N, Glas M, Hillmer AM, Cichon S, Smith AA, Pietsch T, Liu Y, Reynolds BA, Yachnis A, Pincus DW, Simon M, Brustle O, Steindler DA, Scheffler B (2017) Functional subclone profiling for prediction of treatment-induced intratumor population shifts and discovery of rational drug combinations in human glioblastoma. Clin Cancer Res 23:562\u2013574","journal-title":"Clin Cancer Res"},{"key":"4050_CR37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12967-019-1846-y","volume":"17","author":"N Sch\u00e4fer","year":"2019","unstructured":"Schafer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B, Glas M (2019) Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. J Transl Med 17:96","journal-title":"J Transl Med"},{"key":"4050_CR38","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, Investigators CT (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383:2018\u20132029","journal-title":"N Engl J Med"},{"key":"4050_CR39","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ (2017) Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18:1590\u20131599","journal-title":"Lancet Oncol"},{"key":"4050_CR40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, Investigators F (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125","journal-title":"N Engl J Med"},{"key":"4050_CR41","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/cas.14067","volume":"110","author":"M Takahashi","year":"2019","unstructured":"Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K (2019) Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci 110:2247\u20132257","journal-title":"Cancer Sci"},{"key":"4050_CR42","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Dieras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK (2020) A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 26:5310\u20135319","journal-title":"Clin Cancer Res"},{"key":"4050_CR43","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R (2017) \u2019Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD anderson precision medicine study. JCO Precis Oncol 1:1\u20138","DOI":"10.1200\/PO.17.00002"},{"key":"4050_CR44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/nos273","volume":"15","author":"M Weller","year":"2013","unstructured":"Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma\u2013are we there yet? Neuro Oncol 15:4\u201327","journal-title":"Neuro Oncol"},{"key":"4050_CR45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Le Rhun E (2020) How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev 87:102029","journal-title":"Cancer Treat Rev"},{"key":"4050_CR46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186","journal-title":"Nat Rev Clin Oncol"},{"key":"4050_CR47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/neuonc\/noaa215.179","volume":"22","author":"P Wen","year":"2020","unstructured":"Wen P, Trippa L, Lee E, Fell G, Rahman R, Arrillaga-Romany I, Touat M, McCluskey C, Brunno J, Gaffey S, Drappatz J, Lassman A, Galanis E, Ahluwalia M, Colman H, Nabors L, Hepel J, Elinzano H, Schiff D, Chukwueke U, Beroukhim R, Nayak L, Mcfaline-Figueroa J, Batchelor T, Rinne M, Kaley T, Lu-Emerson C, Bi WL, Arnaout O, Peruzzi P-P, Doherty L, Haas-Kogan D, Tanguturi S, Cagney D, Aizer AA, Welch M, Lavallee M, Fisher-Longden B, Dowling S, Geduldig J, Santagata S, Meredith D, Chiocca EA, Reardon D, Ligon K, Alexander B (2020) \u2019Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGhT): a phase II platform trial using Bayesian adaptive randomization. Neuro Oncol 22:44\u201344","journal-title":"Neuro Oncol"},{"key":"4050_CR48","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972","journal-title":"J Clin Oncol"},{"key":"4050_CR49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/noy161","volume":"21","author":"W Wick","year":"2019","unstructured":"Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M (2019) N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol 21:95\u2013105","journal-title":"Neuro Oncol"},{"key":"4050_CR50","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954\u20131963","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04050-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:10:27Z","timestamp":1688213427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04050-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4050"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04050-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lazaros Lazaridis received honoraria and travel support from Novocure. Teresa Schmidt received honoraria and travel support from Novocure. Jens T. Siveke reports research funding from BMS, Celgene and Roche; consulting and personal fees from AstraZeneca, Bayer, Baxalta, BMS, Celgene, Immunocore, Lilly, Novartis, Roche, Shire; has minor equity in FAPI Holding and Pharma15 (<\u20093%) and is a member of the Board of Directors for Pharma15 outside the submitted work. Jens T. Siveke is supported by the German Cancer Consortium (DKTK). Sebastian Bauer reports personal fees from Deciphera, grants from Incyte, grants and personal fees from Blueprint Medicines, personal fees from Lilly, grants and personal fees from Novartis, personal fees from Daichii-Sankyo, personal fees from Plexxikon, personal fees from Exelixis, personal fees from Bayer, and others from Pfizer, during the conduct of the study; personal fees from Pharmamar, personal fees from Lilly, personal fees from Roche, and personal fees from GSK, outside the submitted work. Bj\u00f6rn Scheffler is supported by the German Cancer Consortium (DKTK) and the DFG-CRU337. Sied Kebir received honoraria and travel support from Novocure. Martin Glas reports honoraria from Roche, Novartis, UCB, Abbvie, Daiichi Sankyo, Novocure, Bayer, Janssen-Cilag, Medac, Merck, Kyowa Kirin; travel support from Novocure and Medac; research grant from Novocure. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University Duisburg-Essen (August 12, 2020; application number: 20\u20139431-BO).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study (retrospective and anonymous analysis) formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}